Obesity

Stanford’s AI Pipeline Uncovers BRP, an Appetite-Suppressing Peptide With a New Mechanism

by
Stanford’s AI Pipeline Uncovers BRP, an Appetite-Suppressing Peptide With a New Mechanism

Researchers at Stanford Medicine have used a computational screening pipeline to identify a naturally occurring peptide that curbs appetite in animals without the digestive side effects that make semaglutide — the active ingredient in Ozempic and Wegovy — difficult for some patients to tolerate. The molecule, a 12-amino-acid peptide dubbed BRP, was described in a … Read more

EloraTZP Hits 23.3% Weight Loss in Phase 2b, but 25% Dropout Rate Raises Flags

by
EloraTZP Hits 23.3% Weight Loss in Phase 2b, but 25% Dropout Rate Raises Flags

The race to build a more potent obesity drug has a new benchmark. A combination therapy called EloraTZP, developed by Eli Lilly, produced 23.3% average body-weight loss over 48 weeks in a mid-stage trial — the strongest result the company has reported for any incretin-based programme to date. The findings were presented at the European … Read more